Symphony a new product with FDA approval expected 2020, page-5

Very excited! ARX marker will cover what PNV has presence in impaired healing likediabetic foot ulcers and venous leg ulcers when Symphony is granted by FDA!

Quoted below:

Aroa also has a pipeline of additional products under development based on the Endoform® technology. This includes Symphony, a skin substitute for closing wounds in patients with severely impaired healing (e.g. diabetic foot ulcers and venous leg ulcers) and a single-use negative pressure wound therapy (sNPWT) product with an Endoform® interface for complex wounds and dead space management.